Hexarelin Research: Trials, Data & What the Studies Show
Hexarelin produces the strongest acute growth hormone pulse of the GHRP class — and has a separate, GH-independent cardiac literature. The human endocrine data also documents desensitisation and off-target hormone release that shape how the compound is studied.
Mechanism of action
Hexarelin (also called Examorelin) is a synthetic six-amino-acid growth hormone-releasing peptide that acts as a potent agonist at the ghrelin / growth hormone secretagogue receptor (GHSR).
Binding at GHSR in the hypothalamus and anterior pituitary triggers an immediate pulse of endogenous human growth hormone. Among GHRPs, Hexarelin produces the largest acute peak.
Separately, it binds peripheral receptors in cardiovascular tissue — GHSR and the CD36 scavenger receptor in heart and blood vessel cells. This second pathway is the basis for the cardiac findings below and operates independently of growth hormone.
The studies
Hexarelin's literature splits into two distinct halves: human endocrine dosing work on growth hormone output, and largely preclinical cardiovascular and metabolic work driven by CD36 binding. The research-context section at the end is drawn from the human data.
Growth hormone axis
Rising-dose growth hormone response in healthy adults
Whether Hexarelin can reliably force high-volume endogenous growth hormone secretion in humans.
Double-blind placebo-controlled rising-dose trials in healthy adult male cohorts · peak serum GH, 24-hour mean GH production rate, secretory burst mass
- Greater than GHRH
- Peak serum GH
- Elevated
- 24-hour mean GH production
- Larger secretory burst mass
- Mechanism of increase
- Hexarelin produced a higher peak growth hormone response than standard GHRH in direct comparison.
- Dosing two to three times daily raised the 24-hour mean GH production rate.
- The increase came from amplifying the mass of each secretory burst rather than adding extra pulses.
Cardiovascular
GH-independent protection in ischaemia-reperfusion injury
Whether Hexarelin protects cardiac tissue independently of growth hormone signalling.
Ischaemia-reperfusion model in hypophysectomised subjects — animals physically unable to produce growth hormone, isolating the peripheral pathway
- Reduced
- Ischaemia-reperfusion damage
- Preserved
- Left ventricular end-diastolic pressure
- Reduced
- Creatine kinase leakage
- Using hypophysectomised subjects is what makes this study important: the protection appeared with no growth hormone available at all.
- Cardiac tissue was defended against ischaemia-reperfusion injury and coronary vessel integrity was maintained.
- Reduced creatine kinase leakage indicates fewer cardiac cells were dying, not merely better haemodynamics.
Cardiac fibrosis, inflammatory markers and autonomic balance
Whether Hexarelin can prevent or reverse scarring of the heart wall after infarction and reduce the inflammatory response.
Post-myocardial-infarction tissue profiling with cytokine panels and autonomic nervous system measures
- Prevented / reversed
- Cardiac fibrosis
- Downregulated
- TNF-α and IL-1β
- Shifted parasympathetic
- Autonomic balance
- Anti-fibrotic effect was observed both as prevention of new scarring and reduction of existing fibrosis.
- Pro-inflammatory cytokines TNF-α and IL-1β were directly downregulated.
- The autonomic shift away from sympathetic dominance is an additional, separate mechanism from the cytokine effect.
Metabolic & vascular
CD36 binding, atherosclerotic lipid uptake and insulin sensitivity
Whether CD36 binding translates into reduced plaque lipid uptake and improved metabolic profile.
Molecular screening of cellular fat uptake and gene expression in vascular and adipose tissue, plus metabolic disease models
- Reduced
- Oxidised LDL uptake
- Corrected
- Insulin intolerance
- Reduced
- Adipocyte size
- Increased
- UCP-1 expression
- Tight CD36 binding reduces uptake of oxidised LDL by vessel wall cells, the initiating step in plaque formation.
- In metabolic disease models, lipid abnormalities and insulin intolerance both improved.
- Raised UCP-1 expression and smaller adipocytes point to increased thermogenic fat activity — this is preclinical only.
Research context
Desensitisation and off-target hormone release
How the growth hormone response behaves over sustained administration, and how selective the compound actually is.
16-week human tracking of pituitary GH response, with acute-dose measurement of cortisol, ACTH and prolactin
- Blunted
- GH response over 16 weeks
- Transiently elevated
- Cortisol and ACTH
- Mildly elevated
- Prolactin
- The pituitary builds tolerance: GH response weakens significantly over sustained administration, so continuous use is not supported by the data.
- Unlike Ipamorelin, Hexarelin is not selective — acute doses raise cortisol and ACTH, with mild prolactin elevation.
- These two findings are the main reason Hexarelin did not progress as a long-term therapeutic despite its potency.
Storage & handling
Hexarelin is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until dissolved and never shake.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.